Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive.

{
  "signal_id": "0f4bfc9a-4f7a-48dd-8e0a-fb3dd78da213",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-05-13T10:42:32+00:00",
  "company": {
    "name": "Isomorphic Labs",
    "domain": "isomorphiclabs.com"
  },
  "data": {
    "url": "https://european-biotechnology.com/latest-news/isomorphic-labs-raises-2-1b-for-ai-enabled-drug-discovery-drive",
    "title": "Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive.",
    "excerpt": "Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive.\n\nIsomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.\n\nLondon-based Isomorphic spun off from DeepMind, an AI business owned by Google's parent company, in 2021. Building on DeepMind's use of AI system AlphaFold 2 to predict protein structures, the startup set itself the goal of reimagining drug discovery in light of emerging capabilities. Isomorphic later opened an office in Switzerland, raised $600 million and partnered with Eli Lilly, Novartis and Johnson & Johnson.\n\nIsomorphic, which European Biotechnology Magazine named as its top startup to watch in 2026, has now raised more money. The series B round positions Isomorphic to keep developing and deploying its AI drug design engine, IsoDDE. Isomorphic, which opened a site in Massachusetts last year, plans to scale globally, including by hiring AI, engineering, drug design and clinical employees across its sites.\n\nThe plan reflects Isomorphic's belief that scaling globally is crucial to its long-term vision of applying AI to complex biological and medical challenges to address the global burden of disease. The vision has informed Isomorphic's use of its technology to discover drug candidates for internal development.\n\nIsomorphic's financing will support the...",
    "product": "artificial intelligence engine and advance drugs discovered using the platform",
    "summary": "Isomorphic Labs Limited is developing artificial intelligence engine and advance drugs discovered using the platform.",
    "planning": false,
    "image_url": "https://european-biotechnology.com/wp-content/uploads/2026/05/getty-images-aTWKwJllPOA-unsplash-1030x579.jpg",
    "confidence": 0.8322,
    "assets_tags": [
      "research_and_development"
    ],
    "product_data": {
      "full_text": "artificial intelligence engine and advance drugs discovered using the platform",
      "fuzzy_match": true
    },
    "product_tags": [
      "online_technology",
      "general_technology",
      "medical",
      "future_tech"
    ],
    "published_at": "2026-05-13T10:42:32Z",
    "job_title_tags": [
      "general_technology",
      "data_analysis"
    ],
    "article_sentence": "Isomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform."
  }
}

curl https://signals.autobound.ai/v1/signals/0f4bfc9a-4f7a-48dd-8e0a-fb3dd78da213 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"isomorphiclabs.com","limit":20}'